NCT06282809招募中不适用
The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy
研究概览
简要总结
The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy.
详细描述
This is a prospective multi-center, single-arm, feasibility trial designed to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinoma tumors in patients who are diagnosed with unresectable locally advanced (Stage 3) or oligometastatic disease (Stage 4).
The type of design is exploratory and is considered interventional. Following histotripsy, subjects will undergo imaging ≤36-hours post-index procedure. Additionally, subjects will be followed at 7-day, 14-day, 30-day, 60-day, 120-day, and 180-day timepoints.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is ≥18 years of age.
- •Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
- •Subject is diagnosed with unresectable pancreatic adenocarcinoma (locally advanced [Stage 3] or oligometastatic disease [Stage 4]) confirmed via CT or MR imaging ≤14 days prior to the planned index procedure.
- •NOTE: If Stage 4 disease, there must be ≤5 metastatic tumors, the tumors must be located only in the liver and/or lung, and the metastatic tumors must be stable.
- •Subject is not a surgical candidate and has received chemotherapy ≥8 weeks.
- •Subject can tolerate general anesthesia.
- •Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-1 at baseline.
- •Subject meets the following criteria ≤14 days prior to the planned index procedure date:
- •Hemoglobin ≥ 9 g/dL,
- •Neutrophil count >1.0 x 10^9/L,
- •Platelet >50 x 10^9/L,
- •Total bilirubin ≤2.5x Institutional Upper Limit of Normal (IULN),
- •Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5x IULN,
- •International Normalized Ratio (INR) value <1.5,
- •Serum creatinine <2.0mg/dL or an estimated glomerular filtration rate (eGFR) ≥45mL/min.
- •The targeted pancreatic tumor is ≥2 cm in longest diameter.
- •The planned histotripsy treatment volume is ≥1.0 cm from any portion of the duodenum, small intestine, stomach, or colon as visualized on ultrasound, and CT, or MR imaging.
- •Subject has an adequate acoustic window to visualize targeted tumor using the HistoSonics Edison System.
- •Subject will undergo histotripsy treatment of only one (1) tumor during the index procedure, regardless of how many tumors are present in the pancreas.
排除标准
- •Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period.
- •Subject has had prior pancreatic, bilioenteric, or gastric surgery.
- •Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.
- •Subject has an uncorrectable coagulopathy.
- •Subject has a life expectancy of less than six (6) months.
- •Subject has a biliary or pancreatic stent and/or percutaneous biliary tube that encompasses the planned histotripsy treatment volume.
- •Subject has metastases to organs other than the liver and/or lung (e.g., bone, brain, peritoneum).
- •Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
- •Subject has an active duodenal or gastric ulcer requiring medical management.
- •Subject is undergoing active chemotherapy for any cancer ≤7 days prior to planned index procedure date.*
- •Subject is undergoing active immunotherapy or targeted therapies ≤30 days prior to planned index procedure date.
- •Subject's targeted tumor has had prior locoregional therapy (e.g., ablation, embolization, or radiation).
- •Subject has a planned cancer treatment (e.g., pancreatic surgery, targeted therapy, immunotherapy) exclusive of chemotherapy, ≤30 days post index procedure.
- •Subject has planned chemotherapy ≤14 days post index procedure.*
- •Subject has not recovered (CTCAE grade 2 or better) from chemotherapy or immunotherapy related toxicities (exclusive of alopecia, neuropathy, and exocrine insufficiency).
- •In the investigator's opinion, histotripsy is not a treatment option for the subject.
- •Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
- •Subject's tumor is not treatable by the System's working ranges (refer to User Guide).
- •(*) Subject must not be off chemotherapy >21 days in total.
研究组 & 干预措施
HistoSonics System
Experimental
干预措施: HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy (Device)
结局指标
主要结局
Evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy
时间窗: 30 days post histotripsy procedure
Index procedure-related complications ≤30 days post index procedure, graded using Clavien-Dindo Classification and Common Terminology Criteria for Adverse Events (CTCAE). \[Clinical Events Committee Adjudicated\]
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)Renal CancerTumor, SolidKidney CancerTumor, BenignTumorNCT05820087HistoSonics, Inc.67
已完成
不适用
The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using HistotripsyRenal CancerTumor, SolidKidney CancerTumor, BenignKidney NeoplasmsTumorNCT05432232HistoSonics, Inc.20
招募中
不适用
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)Liver NeoplasmsPrimary Liver CancerSecondary Liver CancerTumor LiverBenign Liver TumorNCT06486454HistoSonics, Inc.5,000
Unknown
不适用
Comparison Between the Effect of Ultrasound Debridement and Conventional Treatment in Diabetic Foot Ulcers (DFU).Diabetic Foot UlcerNCT04716790Universidad Complutense de Madrid60
已完成
不适用
Treatment of Subcutaneous Adipose Tissue in the Thighs Using High Intensity Focused UltrasoundTreatment of Adipose Tissue in the ThighsNCT01823653Solta Medical60